ProShare Advisors
EVLO

ProShare Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

ProShare Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-561
Closed -$37K – 2228
2022
Q1 		$37K Sell
561
-147
-21% -$12.2K ﹤0.01% 2135
2021
Q4 		$86K Buy
+708
New +$120K ﹤0.01% 2222

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's EVLO Position: Q2 2022 in Review

ProShare Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 561 shares — an estimated $37K sold.

ProShare Advisors first reported a position in EVLO in Q4 2021 and held it in 2 quarters. The position peaked at $86K in Q4 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • ProShare Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 561 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $37K.
  • ProShare Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • ProShare Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $86K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.